Corvus Pharmaceuticals (CRVS) Stock: Buy, Sell, or Hold?
CRVS - Corvus Pharmaceuticals, Inc.
$10.53
-0.12 (-1.13%)
▼
5d:
+10.61%
30d:
-10.76%
90d:
-18.5%
BUY
HIGH Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 03, 2026
9d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Oct 20, 2026 at $10.12 · last confirmed Oct 23, 2026
Strength: 8.1/10
Get Alerted When CRVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CRVS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: CRVS shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: CRVS is currently trading at $10.53, which is considered fair relative to its 30-day fair value range of $9.92 to $12.20.
Technical Outlook: Technically, CRVS is in a downtrend. The price is approaching resistance at $10.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRVS scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $33.14 (+214.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRVS is in a downtrend. The price is approaching resistance at $10.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRVS scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $33.14 (+214.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$9.92 -
$12.20
Company Quality Score
61/100
(BUY)
Options IV Signal
36th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 36th percentile)
- BULLISH: Strong technical setup (84/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 214.7% below Wall St target ($33.14)
- BULLISH: Bottoming setup score 84/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$9.92 -
$12.20
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$1.29
(12.2%)
Support & Resistance Levels
Support Level
$9.21
Resistance Level
$10.68
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.86
Wall Street Target
$33.14
(+214.7%)
Share & Embed Analysis
Last updated: October 24, 2026 2:00 AM ET
Data refreshes hourly during market hours. Next update: 3:00 AM
Data refreshes hourly during market hours. Next update: 3:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRVS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 58 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 75 BUY |
Advanced CRVS Option Strategies
Professional options setups generated by AI based on today's CRVS price and gamma walls.
